•  
• Tweet
•  
•  
•        Print
•  
•        Email
•  
•         Track Keywords

The Fund invests in venture companies founded by Maximon, the Swiss longevity company builder, which are promoting longevity and healthy aging with supporting research in esteemed universities as well as with their products and services or which support an active and healthy aging in society.

Longevity is the science of anti-aging research and rejuvenation and has experienced an unprecedented advancement over recent years, particularly with the discovery that the rate of aging is controlled and can be modulated, at least to some extent, by genetic pathways and biochemical processes. Longevity identifies both lifestyle and pharmaceutical targets to improve the human health-span (i.e. the time we can live without negative impacts from aging).

Dr. Tobias Reichmuth, Founding Partner at Maximon, states: "Longevity is the new big investment opportunity. There is simply nobody who wouldn't want to age in good health. Need I say more?". Maximon Founding Partner Marc P. Bernegger adds: "The recent progress in extending and enforcing a healthy lifespan is very impressive and creates unique and massive investment opportunities. We already have substantial subscription requests for the fund's next closing".

The Longevity Co-Investment Fund (LCIF) invests up to CHF 10 million per company, which allows to finance up to 10-12 start-ups in this fast growing industry over the next four years. The LCIF will remain open for investors for the next 18+ months.